The new generation of antithrombotic agents, known as Direct Oral Anticoagulants (DOACs),
act on a single factor within the coagulation cascade. Although the monitoring of
therapy is not necessary for DOACs, measuring the anticoagulant effect is useful in
many clinical situations, especially pre-operative evaluation [
[1]
]. Specific tests, which quantify the drug indirectly, and nonspecific tests, which
are altered by DOACs, are used to evaluate the anticoagulant effect of DOACs. The
aim of this study is to assess the responsiveness of the specific and non-specific
assays used at IRCCS Policlinico San Donato to low DOAC concentrations and to compare
the responsiveness between calibrators and patients with nonspecific assays.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- To measure or not to measure direct oral anticoagulants before surgery or invasive procedures.J Thromb Haemost. 2016; 14: 1325-1327
- Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.Thromb Haemost. 2012; 107: 985-997
- Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: Results from a multicenter/multiplatform study.J Thromb Haemost. 2016; 14: 2194-2201
- Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology.Br J Haematol. 2012; 159: 427-429
- Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and Standardisation Committee of the International Society on thrombosis and haemostasis.J Thromb Haemost. 2013; 11: 756-760
- Sensitivity of routine coagulation assays to direct oral anticoagulants: Patient samples versus commercial drug-specific calibrators.Pathology. 2016; 48: 712-719
- Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.Thromb Haemost. 2015; 113: 77-84
- Performance of coagulation tests in patients on therapeutic doses of dabigatran: A cross-sectional pharmacodynamic study based on peak and trough plasma levels.J Thromb Haemost. 2013; 11: 1493-1502
- How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study.Clin Chem Lab Med. 2015; 53: 265-273
Article info
Publication history
Published online: October 12, 2018
Accepted:
October 9,
2018
Received:
October 2,
2018
Identification
Copyright
© 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
